tiprankstipranks
Fisher & Paykel Healthcare Corporation Limited (FSPKF)
OTHER OTC:FSPKF
US Market
FSPKF
Fisher & Paykel Healthcare Corporation Limited
RESEARCH TOOLSreports

Fisher & Paykel Healthcare Corporation Limited (FSPKF) Stock Forecast & Price Target

61 Followers
See the Price Targets and Ratings of:

FSPKF Analyst Ratings

Moderate Buy
9Ratings
Moderate Buy
5 Buy
4 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Fisher
& Paykel Healthcare Corporation Limited
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

FSPKF Stock 12 Month Forecast

Average Price Target

$25.22
▲(9.54% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Fisher & Paykel Healthcare Corporation Limited in the last 3 months. The average price target is $25.22 with a high forecast of $28.36 and a low forecast of $20.17. The average price target represents a 9.54% change from the last price of $23.02.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"$18","29":"$29","20.75":"$20.8","23.5":"$23.5","26.25":"$26.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28.355075,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.215106333333335,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.170398,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.17</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,20.75,23.5,26.25,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.375,21.911928846153845,22.44885769230769,22.98578653846154,23.522715384615385,24.05964423076923,24.596573076923075,25.13350192307692,25.67043076923077,26.207359615384615,26.74428846153846,27.28121730769231,27.81814615384615,{"y":28.355075,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.375,21.670392794871795,21.96578558974359,22.261178384615384,22.55657117948718,22.851963974358974,23.14735676923077,23.442749564102563,23.73814235897436,24.033535153846156,24.32892794871795,24.624320743589745,24.91971353846154,{"y":25.215106333333335,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.375,21.282338307692307,21.189676615384617,21.097014923076923,21.00435323076923,20.91169153846154,20.819029846153846,20.726368153846153,20.63370646153846,20.54104476923077,20.448383076923076,20.355721384615382,20.263059692307692,{"y":20.170398,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.403,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.961,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.884,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.884,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.818,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.818,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.431,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.26,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.875,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.095,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.02,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.02,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.375,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$28.36Average Price Target$25.22Lowest Price Target$20.17
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on FSPKF
Chris Cooper
J.P. Morgan
J.P. Morgan
$26.99
Buy
17.25%
Upside
Reiterated
05/27/26
J.P. Morgan Sticks to Their Buy Rating for Fisher & Paykel Healthcare Corporation Limited (FSPKF)
Canaccord Genuity Analyst forecast on FSPKF
Shane Storey
Canaccord Genuity
Canaccord Genuity
$26.2
Buy
13.82%
Upside
Reiterated
05/27/26
Analysts Are Bullish on Top Healthcare Stocks: Rapid Micro Biosystems (RPID), Fisher & Paykel Healthcare Corporation Limited (FSPKF)
Citi Analyst forecast on FSPKF
Laura Sutcliffe
Citi
Citi
―
Hold
―
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) and CareDx (NASDAQ: CDNA)
Macquarie Analyst forecast on FSPKF
Christine Trinh
Macquarie
Macquarie
―
Buy
―
Reiterated
05/27/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on FSPKF
Marcus Curley
UBS
UBS
―
Hold
―
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: Tecan Group AG (Other OTC: TCHBF) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Jefferies Analyst forecast on FSPKF
Vanessa Thomson
Jefferies
Jefferies
$25.84
Buy
12.26%
Upside
Reiterated
05/26/26
Jefferies Keeps Their Buy Rating on Fisher & Paykel Healthcare Corporation Limited (FSPKF)
RBC Capital Analyst forecast on FSPKF
Craig Wong-Pan
RBC Capital
RBC Capital
$20.17
Hold
-12.38%
Downside
Upgraded
05/26/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) and Corbus Pharmaceuticals (NASDAQ: CRBP)
Morgan Stanley Analyst forecast on FSPKF
David Bailey
Morgan Stanley
Morgan Stanley
$23.73
Buy
3.08%
Upside
Reiterated
05/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sumitomo Dainippon Pharma Co (Other OTC: DNPUF) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Jarden Analyst forecast on FSPKF
Adrian Allbon
Jarden
Jarden
$28.36
Hold
23.18%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Health Catalyst (NASDAQ: HCAT) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Goldman Sachs Analyst forecast on FSPKF
Davinthra Thillainathan
Goldman Sachs
Goldman Sachs
$30.72→$31.66
Buy
37.52%
Upside
Reiterated
02/23/26
Analysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) and Vir Biotechnology (NASDAQ: VIR)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on FSPKF
Chris Cooper
J.P. Morgan
J.P. Morgan
$26.99
Buy
17.25%
Upside
Reiterated
05/27/26
J.P. Morgan Sticks to Their Buy Rating for Fisher & Paykel Healthcare Corporation Limited (FSPKF)
Canaccord Genuity Analyst forecast on FSPKF
Shane Storey
Canaccord Genuity
Canaccord Genuity
$26.2
Buy
13.82%
Upside
Reiterated
05/27/26
Analysts Are Bullish on Top Healthcare Stocks: Rapid Micro Biosystems (RPID), Fisher & Paykel Healthcare Corporation Limited (FSPKF)
Citi Analyst forecast on FSPKF
Laura Sutcliffe
Citi
Citi
―
Hold
―
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) and CareDx (NASDAQ: CDNA)
Macquarie Analyst forecast on FSPKF
Christine Trinh
Macquarie
Macquarie
―
Buy
―
Reiterated
05/27/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on FSPKF
Marcus Curley
UBS
UBS
―
Hold
―
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: Tecan Group AG (Other OTC: TCHBF) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Jefferies Analyst forecast on FSPKF
Vanessa Thomson
Jefferies
Jefferies
$25.84
Buy
12.26%
Upside
Reiterated
05/26/26
Jefferies Keeps Their Buy Rating on Fisher & Paykel Healthcare Corporation Limited (FSPKF)
RBC Capital Analyst forecast on FSPKF
Craig Wong-Pan
RBC Capital
RBC Capital
$20.17
Hold
-12.38%
Downside
Upgraded
05/26/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) and Corbus Pharmaceuticals (NASDAQ: CRBP)
Morgan Stanley Analyst forecast on FSPKF
David Bailey
Morgan Stanley
Morgan Stanley
$23.73
Buy
3.08%
Upside
Reiterated
05/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sumitomo Dainippon Pharma Co (Other OTC: DNPUF) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Jarden Analyst forecast on FSPKF
Adrian Allbon
Jarden
Jarden
$28.36
Hold
23.18%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Health Catalyst (NASDAQ: HCAT) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Goldman Sachs Analyst forecast on FSPKF
Davinthra Thillainathan
Goldman Sachs
Goldman Sachs
$30.72→$31.66
Buy
37.52%
Upside
Reiterated
02/23/26
Analysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) and Vir Biotechnology (NASDAQ: VIR)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Fisher & Paykel Healthcare Corporation Limited

3 Months
Davinthra ThillainathanGoldman Sachs
Success Rate
3/5 ratings generated profit
60%
Average Return
+2.96%
Copying Davinthra Thillainathan's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.96% per trade.
1 Year
Shane StoreyCanaccord Genuity
Success Rate
6/9 ratings generated profit
67%
Average Return
+5.97%
Copying Shane Storey's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +5.97% per trade.
2 Years
Shane StoreyCanaccord Genuity
Success Rate
6/9 ratings generated profit
67%
Average Return
+5.09%
Copying Shane Storey's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +5.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FSPKF Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
7
6
5
8
8
Hold
4
4
3
5
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
10
8
13
13
In the current month, FSPKF has received 8 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. FSPKF average Analyst price target in the past 3 months is 25.22.
Each month's total comprises the sum of three months' worth of ratings.

FSPKF Financial Forecast

FSPKF Earnings Forecast

Next quarter’s earnings estimate for FSPKF is $0.24 with a range of $0.21 to $0.28. The previous quarter’s EPS was $0.25. FSPKF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year FSPKF has Performed in-line its overall industry.
Next quarter’s earnings estimate for FSPKF is $0.24 with a range of $0.21 to $0.28. The previous quarter’s EPS was $0.25. FSPKF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year FSPKF has Performed in-line its overall industry.

FSPKF Sales Forecast

Next quarter’s sales forecast for FSPKF is $702.57M with a range of $692.92M to $713.16M. The previous quarter’s sales results were $727.58M. FSPKF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year FSPKF has Performed in-line its overall industry.
Next quarter’s sales forecast for FSPKF is $702.57M with a range of $692.92M to $713.16M. The previous quarter’s sales results were $727.58M. FSPKF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year FSPKF has Performed in-line its overall industry.

FSPKF Stock Forecast FAQ

What is FSPKF’s average 12-month price target, according to analysts?
Based on analyst ratings, Fisher & Paykel Healthcare Corporation Limited’s 12-month average price target is 25.22.
    What is FSPKF’s upside potential, based on the analysts’ average price target?
    Fisher & Paykel Healthcare Corporation Limited has 9.54% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is FSPKF a Buy, Sell or Hold?
          Fisher & Paykel Healthcare Corporation Limited has a consensus rating of Moderate Buy which is based on 5 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Fisher & Paykel Healthcare Corporation Limited’s price target?
            The average price target for Fisher & Paykel Healthcare Corporation Limited is 25.22. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $28.36 ,the lowest forecast is $20.17. The average price target represents 9.54% Increase from the current price of $23.02.
              What do analysts say about Fisher & Paykel Healthcare Corporation Limited?
              Fisher & Paykel Healthcare Corporation Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of FSPKF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.